Therapy of osteoporosis in men with teriparatide (Q35496053)

8 August 2017

Therapy of osteoporosis in men with teriparatide (English)

1 reference

8 August 2017

0 references

4

John P Bilezikian

1 reference

8 August 2017

1

Natalie E Cusano

1 reference

8 August 2017

Aline G Costa

2

1 reference

PubMed ID

22132345

8 August 2017

Barbara C Silva

series ordinal

3

1 reference

8 August 2017

25 October 2011

1 reference

8 August 2017

Journal of Osteoporosis

1 reference

8 August 2017

2011

1 reference

8 August 2017

463675

1 reference

Creative Commons Attribution 3.0 Unported

8 August 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Effects of teriparatide retreatment in osteoporotic men and women

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

Management of male osteoporosis: report of the UK Consensus Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

12 July 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F463675

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205768

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22132345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22132345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Skeletal disease in primary hyperparathyroidism

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22132345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4061/2011/463675

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

PubMed ID

22132345